This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Metastatic Colorectal Cancer
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The primary objective of this study is to evaluate the efficacy of Irinotecan in combination with FOLFOX+Bevacizumab versus FOLFOX+Bevacizumab alone in the first-line treatment of patients with metastatic colorectal cancer.

Provided treatments

  • Drug: Oxaliplatin, 5FU/LV, Bevacizumab
  • Drug: 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01321957. The sponsor of the trial is Martin-Luther-Universität Halle-Wittenberg and it is looking for 250 volunteers for the current phase.
Official trial title:
FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study